Acelyrin (SLRN) stock rises on an investor meeting set for Monday to discuss new Phase 2 data for lonigutamab, a drug for ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback